Loading
Adding lenalidomide to rituximab more than doubled the time to progression in relapsed follicular and marginal zone lymphoma compared with rituximab alone, establishing a chemotherapy-free option for relapsed indolent lymphoma.
Phase 3 trial of 358 patients with relapsed or refractory follicular (grade 1 to 3a) or marginal zone lymphoma randomised to lenalidomide plus rituximab (R2) or placebo plus rituximab for 12 cycles.
Median progression-free survival was 39.4 versus 14.1 months (hazard ratio 0.46) and response 78 versus 53 percent; the benefit was clear in follicular lymphoma while the marginal zone subgroup was small and inconclusive. Neutropenia was more frequent with lenalidomide.
Lenalidomide-rituximab is approved for relapsed follicular and marginal zone lymphoma and is a standard chemotherapy-free choice, though marginal zone-specific evidence is thinner.
Shares Lenalidomide, Rituximab, Follicular lymphoma.
Shares Lenalidomide, Rituximab, Follicular lymphoma.
Shares Lenalidomide, Rituximab, Follicular lymphoma.
Shares Lenalidomide, Rituximab, Follicular lymphoma.
Shares Lenalidomide, Rituximab, Follicular lymphoma.
Shares Lenalidomide, Rituximab, Follicular lymphoma.
Shares Lenalidomide, Rituximab, Follicular lymphoma.
Shares Rituximab, Follicular lymphoma.